Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial

Posted on by

Lancet Infectious Diseases
Jan 2022 Volume 22 Number 1 p1-150, e1-e40
https://www.thelancet.com/journals/laninf/issue/current

 

Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial
Vivek Shinde, et al.